Mainstay Medical has announced a significant development in the diagnosis of low back pain following the United States Centers for Disease Control and Prevention (CDC)’s introduction of a new International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis code specifically for multifidus dysfunction in the lumbar region. Effective from October 1, 2024, the new code, M62.85, categorises dysfunction of the multifidus muscles as a distinct clinical condition.
Multifidus dysfunction is often linked to acute injuries in the lower back. When such injuries occur, the brain may inhibit the neural drive that activates the multifidus muscle, leading to decreased muscle activity. As the multifidus is a key stabiliser of the lumbar spine, this reduction can result in joint instability and overloading, further complicating the issue and contributing to chronic low back pain (CLBP).
The introduction of this specific diagnosis code is expected to provide healthcare professionals with a clearer framework for identifying and diagnosing multifidus dysfunction. This is a crucial step, as the CDC recognises multifidus muscle dysfunction as a significant contributor to CLBP. According to Jason Hannon, Chief Executive Officer of Mainstay Medical, the new code reflects the need for precise diagnosis in this area of health care.
The ReActiv8® Restorative Neurostimulation™ system is the only FDA-approved treatment aimed at managing intractable CLBP associated with multifidus muscle dysfunction. It works by delivering electrical stimulation to the nerves that activate the multifidus muscle, thereby aiding in the restoration of its function and facilitating recovery from chronic low back pain.
Hannon highlighted the importance of the new code, stating, “Multifidus dysfunction is a highly specific disease state that does not respond to palliative forms of stimulation. We are excited that this new code provides for clear reflection of the underlying disease state.” This development is anticipated to improve diagnosis and treatment options for patients suffering from CLBP, thereby enhancing their overall quality of life.
As the healthcare community prepares for the implementation of this new diagnosis code, it is hoped that it will lead to more effective treatment strategies for those affected by multifidus dysfunction. Further information can be found at www.mainstaymedical.com.
